Table 2.
Intervention characteristics for clinical studies of patients administered MSCs as a therapeutic intervention for COVID-19.
| Intervention | Total studies, n |
|---|---|
| MSC tissue source | |
| Umbilical cord blood or tissue | 8 |
| Menstrual blood | 1 |
| Bone marrow mononuclear cells | 1 |
| Not described | 1 |
| MSCs fresh or frozen/cryopreserved | |
| Fresh only | 0 |
| Fresh or cryopreserved | 1 |
| Cryopreserved | 4 |
| Not stated | 6 |
| Product dose | |
| MSCs, cells/kg (n=7) | 1-3 × 106 |
| MSCs, total cells (n=4) | 30-100 × 106 |
| Route of administration | |
| Intravenous | 11 |
| No. MSC infusions, patients (%) | |
| 1 | 80 (38.6) |
| 2 | 15 (7.2) |
| 3 | 112 (54.1) |
| MSC passage number | |
| P3 or P4 | 2 |
| P5 | 3 |
| P3–P5 | 1 |
| P5-P6 | 1 |
| Not stated | 4 |
| ISCT criteria | |
| Fully met criteria (A–D below), n | 2 |
| (A) Plastic adherence | 3 |
| (B) Trilineage differentiation | 5 |
| (C) Positive/negative surface markers | 8 |
| (D) MSC viability | 6 |
Abbreviations: NA, not applicable; ISCT, International Society of Cellular Therapy.